Alzheimers 2019 | Frankfurt | Germany | Allied Conferences | Meetings

Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academies Conferences

Theme

Advancements for the Supremacy of Alzheimer?s and Dementia

- Alzheimers 2019

Welcome Message

About Conference

We are back again! The conference dedicated to Innovate Solution to the Public Health Challenges, one conference which future the shape of Dementia and Alzheimers Disease. Our Conference will organize and allow to access the global researchers around the world in a single platform. Alzheimers 2019 will provide a great opportunity beyond any comparison to attend and network with Dementia and Alzheimers Community.

Join us at our 2019 edition of Dementia and Alzheimers Disease to Experience the Global Ambiance with the Researchers who work with the similar significance of the research. Alzheimer's 2019 will help you to get answers to all your queries related to your research work and also it creates a great opportunity to make new associations and also helps to foster potential partnerships. Alzheimers 2019 will be a great platform for you to create a long-lasting relationship with the fellow researchers from Neurology Community.

Get worldwide acknowledgment to your research profile were more than 55000 Visitors who analyzed our conference website to attend and submit proposals of their research work. Where this was recorded as the highest number of Visitors from both, developed and developing nations. While we penetrate the study of visitor, navigation, and traffic patterns to determine the success of our conference website majority amount of traffic we receive from cities like New York, London, Valencia, Amsterdam, Madrid, Barcelona, Athens, Sydney, Paris, Frankfurt, Tokyo, Osaka, Melbourne, Moscow, and Vienna.

Why should you attend?

13th International Conference on Alzheimers Disease and Dementia gives a grand platform for the Organizing Committee Members, international keynote speakers, oral presentations by renowned speakers, Poster presentations, Video Presentations, e-poster presentations, workshops and Exhibitions with delegates from different parts of the world. This conference provides an opportunity to learn to share and find a possible future for Alzheimers. Gives connections between different zoned people

Scientific Sessions/Tracks

Session on: Alzheimers Disease

The healthy human cerebrum contains many billions of neurons— specialized cells that process and transmit data through electrical and chemical signals. They send messages between various parts of the cerebrum, and from the cerebrum to the muscles and organs of the body. Alzheimers disrupts this connection hence the communication among neurons, resulting in loss of function and cell death. Thus this Alzheimers Conference mainly focuses on current research in Alzheimers, its therapeutics and its alternatives.

Session on: Neurodegenerative diseases

Neurodegenerative disease is the progressive loss of structure and function of neurons. This is caused by genetic mutation-common repeat of CAG nucleotide triplet, aggregation of misfolded proteins, membrane intracellular mechanisms such as protein degradation pathway. This is an irreversible loss, and this leads to death. Some of the neurodegenerative disease includes amyotrophic lateral sclerosis, Parkinson’s, Alzheimers and Huntington’s. This Alzheimers Conference includes talks from global neuroscience researchers to explain the recent trends in its therapeutics.

Session on: Amyloid protein in Dementia

The molecular mechanisms & speculations of Alzheimers Disease can be fantastically mind boggling. A best down review took after by expanding profundity and detail might be the most ideal approach to increase understanding. The development of a protein peptide known as amyloid beta which clusters into amyloid plaques on the blood cells and on the outside surface of neurons of the brain, which ultimately leads to the killing of neurons are the key events leading to Alzheimers. Alzheimers Congress and dementia congress are the future insights to discuss amyloid protein in dementia.

Session on: Vascular Dementia

Vascular dementia, is also called in different names such as multi-infarct dementia (MID) and vascular cognitive impairment (VCI), is dementia caused by reduced or damaged blood supply to the brain due to diseased blood vessels. This disorder comprises complex interaction of cerebrovascular disease and their risk factors that lead to changes in the brain structures due to strokes and lesions.

The most widely recognized types of dementia are:

Stroke-related dementia. A stroke happens when blood supply to the cerebrum is all of a sudden cut off. This may cause issues with development, coordination, speech or sight depending upon the part of the cerebrum affected. The second one is subcortical vascular dementia. This is caused by changes to very small veins in the brain. They cause memory and thinking to get worse over time, unlike the sudden change that can happen after a stroke. Vascular dementia needs immediate cure since it affects the blood supply, Dementia Conferences and dementia Congresses plays a major role in gathering people to discuss and enumerate the possibilities.

Session on: Dementia with Lewy bodies

Lewy body dementia, otherwise called as dementia with Lewy bodies, is the second most common kind of progressive dementia after Alzheimers. Protein deposits, called Lewy bodies, gets deposited in nerve cells in the brain regions involved in thinking, memory and movement. Lewy body dementia causes a progressive decrease in mental health. It causes visual hallucinations, and changes in alertness, attention, inflexible muscles, moderate development and tremors.

Session on: Parkinson’s Disease

Loss of dopamine-producing brain cells leads to progressive deterioration of brain function. The origin of this disease in unknown but it is believed that genetic and environmental factors play a major role in it. Like any other neurodegenerative disease, Parkinsons too has no cure but the symptoms can be controlled by antiparkinson medication levodopa (L-DOPA) as the symptoms progress neurons tend to die and they tend to lose control over non-motor and motor functions. Initially person affected with Parkinson’s suffer from rigidity, stiffness, slowness in movement, difficulty in walking, thinking that eventually leads to much severe symptoms like hallucination, delusion etc. The Dementia conference provides a platform for Parkinsons and its preventive ideologies.

Session on: Geriatrics and cognitive disorder

Alzheimers is as of now positioned as sixth driving reason for death in USA, yet late gauges show that the disorder may rank 3rd, simply behind heart issues and tumor, as a reason for death for more seasoned individuals. The most serious hazard factor for Alzheimers is age, trailed by the family history of the disorder. With couple of special cases, researchers trust Alzheimers is not caused by a single factor or quality, but rather by a blend of components acting together. Alzheimer is an incessant sickness, as discussed previously in Dementia Conference. There is no cure for the disorder, however there are successful medicines to deal the progress with the indications and moderate the movement. Numerous families regularly decrease the manifestations of dementia as a typical procedure of maturing, yet dementia is not a characteristic piece of maturing. Most of the Americans have never encounter noteworthy memory misfortune or any type of dementia. Where Alzheimers sickness more often than not starts after age 65, albeit Alzheimers has been analysed in people under age 65.This can be overcome by different alternative therapeutics such as diet , exercise and socialization ,based on Alzheimers Congresses ,dementia Congresses.

Session on: Biomarkers in Alzheimers

Biomarker are biological marker that is an indicator of normal biological processes, pathogenic cycle or pharmacological reactions to a therapeutic treatment. Biomarkers in Alzheimers are neurochemical indicators used to diagnose the presence of disease. Here, this biological marker helps in identifying the disease in much early state. beta amyloid (Abeta) is an indicator to Alzheimer’s disease. amyloid precursor protein on proteolytic cleavage, A-beta peptide is released, some Abeta peptides that are solubilized are distinguished in CSF and blood plasma which makes AB peptides a promising possibility for bio-marker. Beta-amyloid biomarker indicates 80% or above specificity, in differentiating Alzheimers from dementia. It is assumed that beta-amyloid as a biomarker will give a future to Alzheimers disease.

Session on: Diagnosis and Prognosis of Alzheimers

Medical history of the person, routine task management, changes in behavior

Tests on memory, problem solving, attention and language skills

Basic check-ups such as urine, blood and spinal fluid

Brain scans such as CT or MRI

Prognosis:Currently there are only few medications for Alzheimers and they do not have the power to slow down the symptoms and these medications do not reverse or cure the disease. After a person is diagnosed with Alzheimer, a person can live between 1-20 years, but this might vary from one person to another based on age genetic condition etc. There are a lot of researches that happens, to find a cure to alzheimers. Pfizer and some other company have given up their research on Alzheimer’s. This conference Alzheimers Conference , Alzheimers Congress , Dementia Conference and Dementia Congress play a vital role in the research and hypothesis.

Session on: Alzheimers prevention and risk factors

Risk factors of Alzheimers is not known by scientist, but they have made hypothesis of two known risk factors that is age and genetics. With age it is identified that 60 % of the people are affected and genetics has also been a major drawback. Other factors are stroke, depression, diabetes, head injury, hypothyroidism and cardiovascular problem. Prevention involves eating a healthy diet, maintaining a good work out routing for body and brain.

Session on: Treatment in action

Alzheimers disease is perplexing, and it is far-fetched that any one medication or other mediation can effectively treat it. Current approaches concentrate on helping individuals keep up mental health, oversee behavioral indications, and moderate or postpone the side effects of sickness. Scientists plan to create treatments focusing on hereditary, sub-atomic, and cell systems so the genuine hidden reason for the infection can be ceased or forestalled.

Alzheimers disease inquire about has created to a point where researchers can look into treating side effects to consider tending to basic illness forms. In continuous clinical trials, researchers are creating and testing a few conceivable intercessions, including vaccination treatment, sedate treatments, psychological preparing, physical movement, and medications utilized for cardiovascular sickness and diabetes.

Session on: Alternative treatment for Alzheimers

To delay or prevent Alzheimers disease a lot of herbal cure, dietary supplements and therapeutic nourishment are promoted as memory enhancers or medications. Claims about the safety and effectiveness of these products. The thorough logical research required by the U.S. Sustenance and Drug Administration (FDA) for the endorsement of a professionally prescribed medication isn't required by law for the promoting of dietary supplements or "medicinal foods.

Caprylic corrosive and coconut oil

Concerns

Coenzyme Q10

Coral calcium

Ginkgo biloba

Huperzine A

Omega-3 unsaturated fats

Phosphatidylserine

Tramiprosate

Session on: Caring for the caregiver

People who help the diseased people with their day to day routine, being a companion in sharing their day. Most of the people become aggressive and uncontrollable, in this case the family seek the help of home cares and care takers. They are specially trained people who have the ability to take care of them. They even go to an extent to conduct social events so as to strip off their ideology of isolation.

Session on: Animal models and translational medicine

Animal models for Alzheimers disease is important to consider the human phenotype and what is being demonstrated regarding the animal phenotype. Bradley Hyman, Faculty of neuroscience at Harvard Medical School, said that animal models of Alzheimers disease, based on the genetics of the disease and the closely related frontotemporal dementia, replicate at least some of the pathology. Analysts have been effective at demonstrating quite certain parts of Alzheimers disease in the mouse (e.g., plaques, tangles). Although these models of the human illness, they have been generally welcomed in the field as acceptable models for use in relevant fields of drug discovery

Patients with Alzheimers infection will show both amyloidopathy and tauopathy; animal models are focused on this. A member included that even though the life systems in the mouse is not the same as the human, mutant tau mice are moderately great models in that they summarize tau-subordinate neurodegeneration. This has driven numerous organizations to center around antibodies that piece tau-subordinate neurodegeneration in these mouse models. This session incorporates Transgenic models, Pharmacological models, Natural and semi-natural models, Primate models, Zebrafish models, animal models of human psychological maturing, Development of new animal models, Genetics of translational models, Protein-protein associations, Ethical issues with animal models.

Session on: Clinical trials and case report

Clinical trial is the last and most important test. without this, a drug can’t be published as safe and viable one. Without human volunteer’s in clinical research a drugs history can’t be learnt, and Alzheimers ailment can’t be figured out.

Clinical research that includes individual, paying little attention to whether it is trying an intercession. Clinical examination may involve:

Preclinical Investigation to Clinical Trials

Clinical Studies of Alzheimers

Clinical trial design and methods

Quality of Life Trials

Randomised Clinical Trials

Related associations: Alzheimers Association and Alzheimer's Foundation of America, Alzheimers drug discovery, Alzheimers society of Canada, Alzheimer disease International , Alzheimers foundation of America, Lewy Body Dementia Association , Cure Alzheimers fund , Alzheimers Europe Parkinson Society Canada, American Association of Neurological Surgeons, American Academy of Neurology, World Federation of Neurology , Stroke Association, Spanish Society of Neurology, American Academy of Neurology, Alzheimers Disease International, Association of Parkinsonism and Related Disorders, World Federation of Neurology

Session on: Business entrepreneur Meet

Alzheimers 2019 objective is to bring all existing and budding bio entrepreneurs together to share present and experiences new challenges and innovations in Alzheimers & Dementia community. Every year, over a million companies are started in the world with about 5–10 of them known as high technology companies. Changing ideas into business ventures is tricky opportunity-recognition step critical in new venture creation. Even though life scientists are the founders of biotech companies, studies have shown that most successful high tech start-ups are founded by a team of two to three individuals with mixed backgrounds, substantial industry experience and a very clear market and product focus at founding. This two days conference will be a highly interactive forum that will bring experts in areas ranging from Alzheimers disease analysis to novel therapeutic techniques and approaches to cure Alzheimer disease. Our outstanding speakers will do talks for 25-30 min and Students do poster presentations from submitted abstracts. Interested business candidates will exhibit their products and some do Workshops.

Related conference: Alzheimers Conference | Alzheimers Congress | Alzheimers Conferences | Dementia Conference | Dementia Congress |Dementia Conferences | Neurology Conference | Neurology Congress | Neurology Conferences | Neuro Disorders Conferences | Neuroscience Conference | Neuroscience Conferences

Market Analysis

Every 3 seconds one person on this planet develops dementia, and in that 70% has been confirmed as Alzheimers. There has been an estimation that 46.8 million individuals are living with Dementia in 2017 and this number is expected to be near to 50 million individuals in 2019. About This number will become two-fold every 20 years, achieving 75 million in 2030 and 131.5 million by 2050. According to a study, 58% of individuals with dementia live in low and middle-income nations, however by 2050, this will increase to 68%. The quickest development in the elderly population is occurring in China, India, and their south Asian and western Pacific neighbors.

Demographic aging is an overall procedure that demonstrates the triumphs of enhanced healthcare in the course of the most recent century. Many are presently living longer and more beneficial lives thus the total populace has a more proportion of older people. Dementia primarily affects older people, despite the fact that there is a developing attention to cases that begin before the age of 65.

Alzheimers disease is the common type of dementia.

The proportions of those with different forms of dementia can be broken down as follows:

Alzheimers disease: 62%

Vascular dementia: 17%

Mixed dementia: 10%

Lewy-body dementia: 4%

Fronto-temporal dementia:2%

Parkinson's dementia: 2%

Other: 3%

The market analysis of various reports says that the aggregate estimation and overall cost of dementia is US$818 billion as of 2017, which signify about 1.09% of worldwide GDP. Around 2021, the worldwide cost of Alzheimers will blow upto a trillion dollar from $818 billion. The reports have shown that dementia alone has increases by 35% since 2010. The report updates on Alzheimers Disease International’s (ADI) data on dementia’s global prevalence, incidence and cost, highlighting dementia’s increasing impact on low and middle income countries (LMICs). This figure incorporates costs credited to casual care and synchronizes expenses of social care and the immediate expenses of medicinal care, the direct medical care costs about 20% of worldwide dementia costs, while direct social sector costs and informal care costs each account for approximately 40%.